We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bristol Myers Squibb (BMS) has been sued for $6.4 billion by former Celgene shareholders for allegedly delaying FDA approval of its cancer drug Breyanzi (lisocabtagene maraleuce). Read More
Emergent BioSolutions was hit with a potential class-action lawsuit on Wednesday, alleging the company made false and misleading statements regarding its manufacturing capabilities and quality control processes at its Bayview facility in Baltimore, Md. Read More
Moderna has struck a fill-and-finish deal with Thermo Fisher Scientific to produce hundreds of millions of doses of Moderna’s messenger RNA-based COVID-19 vaccine at its Greenville, N.C., plant. Read More
In a move to expand its cancer drug offerings, German biotech MorphoSys has entered into an agreement to acquire Cambridge, Mass.-based Constellation Pharmaceuticals for $1.7 billion. Read More
In early May, the World Health Organization listed one of Sinopharm’s COVID-19 vaccines for emergency use, clearing the way for its global distribution through the Covax initiative. Read More
The proposed settlement, which must first be approved by the U.S. District Court for the District of Massachusetts, will go to the consumers who argued the anticompetitive practice deprived them of a lower cost alternative to Intuniv. Read More
Vectura’s portfolio currently includes 13 inhaled and 11 noninhaled products sold by different marketing partners, including Novartis, GlaxoSmithKline and Bayer. Read More
Under the terms of the settlement, the companies will pay their own respective legal fees and Bayer will not make any claims for the $173 million payment. Read More
Vaccine supplies to poorer countries have been significantly impacted by the worsening COVID-19 crisis in India, a major supplier to those countries. Read More
Takeda Pharmaceutical subsidiary Baxalta and Bayer have hashed out a settlement that will dismiss a 2019 jury verdict that ordered Baxalta to pay $173 million for infringing on Bayer’s patents for the hemophilia A drug Adynovate, with Bayer agreeing not to pursue the money it is owed. Read More